Rituximab

Rituximab
Product Description

Rituximab biosimilar, chimeric monoclonal antibody which specifically binds to the transmembrane antigen CD20. Indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Currently >60 000 patients treated, >700 000 vials sold, marketed in 19 countries.

Read more Show less

BIOCAD

  • Country/Region:
    Russian Federation
  • On CPHI since:
    2015
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Russian Federation
More specifications Fewer specifications

BIOCAD

  • Country/Region:
    Russian Federation
  • On CPHI since:
    2015
View company profile

More Products from BIOCAD (2)

  • Netakimab

    Product Netakimab

    ONetakimab – an original humanized monoclonal antibody against IL-17. Approved in Russia for plaque psoriasis. Pending approval for ankylosing spondylitis. BIOCAD will also launch an international Phase III clinical trial with the aim of approval in EU.
  • Prolgolimab

    Product Prolgolimab

    Prolgolimab is the original fully human anti-PD1 monoclonal antibody for the treatment of advanced melanoma, advanced NSCLC and metastatic cervical cancer. Pending approval in Russia for melanoma in 2019. For marketing authorization in EU BIOCAD is starting Phase III clinical trials.